SCHEMBL1055899

SCHEMBL1055899

Cn1nnnc1-c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.53
MAOB P27338 3/20 0.52
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
PKM P14618 1/20 0.50
CYP19A1 P11511 2/20 0.48
ENPP3 O14638 1/20 0.48
ENPP1 P22413 1/20 0.48
GAA P10253 2/20 0.48
MEN1 O00255 1/20 0.48
POLB P06746 1/20 0.48
KMT2A Q03164 1/20 0.48
MGAM O43451 1/20 0.48
SI P14410 1/20 0.48
MGAM2 Q2M2H8 1/20 0.48
PIK3CD O00329 1/20 0.47
PIK3CA P42336 1/20 0.47
PIK3CB P42338 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9016444 0.88 ALOX5 (0.52) MAPTMAOBRAB9ANPC1ENPP3
SCHEMBL12458009 0.84 CHRNB2 (0.49) MAPTMAOBRAB9ASMN1; SMN2NPC1
SCHEMBL21978806 0.80 ENPP3 (0.51) MAPTMAOBRAB9ASMN1; SMN2NPC1
SCHEMBL1059430 0.79 ALDH1A1 (0.51) MAPTRAB9ASMN1; SMN2NPC1L3MBTL1
SCHEMBL31326473 0.78 MAPT (0.59) MAPTMAOBRAB9ASMN1; SMN2NPC1
SCHEMBL31605198 0.78 SMN1; SMN2 (0.49) MAPTMAOBSMN1; SMN2L3MBTL1MEN1
SCHEMBL822762 0.78 SMN1; SMN2 (0.55) RAB9ASMN1; SMN2NPC1L3MBTL1POLB
SCHEMBL8381133 0.78 HSD11B1 (0.41) MAPTRAB9ASMN1; SMN2NPC1MEN1
SCHEMBL22165963 0.77 ENPP3 (0.51) MAPTMAOBRAB9ASMN1; SMN2NPC1
SCHEMBL31605136 0.76 MCL1 (0.47) MAPTMAOBRAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2643310-A1 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS Pfizer Inc (US) 2013-10-02 EP disclosed
WO-2012069948-A1 4- (5-CYANO-PYRAZOL-1-YL) -PIPERIDINE DERIVATIVES AS GPR 119 MODULATORS PFIZER INC. (US) 2012-05-31 WO disclosed
EP-2438051-A1 L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS Pfizer Inc. (US) 2012-04-11 EP disclosed
US-20110020460-A1 GPR 119 MODULATORS PFIZER INC. 2011-01-27 US disclosed
WO-2010140092-A1 L- ( PIPERIDIN-4-YL) -PYRAZOLE DERIVATIVES AS GPR 119 MODULATORS PFIZER INC. (US) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110020460-A1 GPR 119 MODULATORS GPR119, GPR65, GPR88 MAPT 3575/4885MAOB 1966/4885RAB9A 534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.